CV - European Medicines Agency

Curriculum Vitae
PERSONAL INFORMATION
Keikawus Arastéh
WORK EXPERIENCE
2011–Present
Medical Director Vivantes Auguste-Viktoria-Klinikum
Vivantes Auguste-Viktoria-Klinikum, (Germany)
2001–Present
Director of the Department of Internal Medicine, Gastroenterology and Infectious
Diseases
Vivantes Auguste-Viktoria-Klinikum, (Germany)
2000–2000
Deputy Chief Physician of the Department of Internal Medicine, Gastroenterology
and Infectious Diseases
Vivantes Auguste-Viktoria-Klinikum, (Germany)
1998–Present
CEO and Principal Investigator
EPIMED - Gesellschaft für epidemiologische und klinische Forschung in der Medizin mbH, (Germany)
1992–December 1999
Chief Senior Physician of the Immunological Dayclinic, Department of Internal
Medicine, Gastroenterology and Infectious Diseases
Auguste-Viktoria-Klinikum, (Germany)
1983–1992
Assistant Physician of the Department of Internal Medicine, Gastroenterology and
Infectious Diseases
Auguste-Viktoria-Klinikum, (Germany)
EDUCATION AND TRAINING
November 2013–Present
Approval as Specialist in Gastroenterology
Ärztekammer Berlin, (Germany)
2006–Present
Approval as Specialist in Infectious Diseases
Ärztekammer Berlin, (Germany)
2005–Present
Approval as Fellow in Gastroenterology
European Board of Gastroenterology (EBG)
2003–Present
Approval as Specialist in Infectious Diseases
Deutsche Gesellschaft für Infektiologie, (Germany)
2000–Present
Habilitation/ Privatdozent
Freie Universität, Berlin, (Germany)
1991–Present
Completion of medical thesis, (PhD / Dr. med.)
Freie Universität, Berlin, (Germany)
19/1/15
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 1 / 7
Curriculum Vitae
1990–Present
1976–1983
Keikawus Arastéh
Approval as Specialist in Internal Medicine
Medical Studies
Freie Universität Berlin, (Germany)
ADDITIONAL INFORMATION
Expertise
Internal Medicine, Infectious Diseases, Gastroenterology
Principal Investigator of Medical Trials (HIV and Hepatitis)
Publications
► Arasteh K, Hannah A. The role of vascular endothelial growth factor (VEGF) in AIDS-related
Kaposi's sarcoma. Oncologist. 2000;5 Suppl 1:28-31.
► Arasteh KN, Cordes C, Ewers M, Simon V, Dietz E, Futh UM, Brockmeyer NH, L'Age M P. HIVrelated nontuberculous mycobacterial infection: incidence, survival analysis and associated risk
factors. Eur J Med Res. Oct 30 2000;5(10):424-430.
► Arasteh K, Muller M. [New antiretroviral drugs. Improved pharmacokinetics and simpler dose
schedules]. MMW Fortschr Med. Apr 2 2001;143 Suppl 1:14-17.
► Arasteh K, Wood R, Muller M, Prince W, Cass L, Moore KH, Dallow N, Jones A, Klein A, Burt V,
Kleim JP. GW420867X administered to HIV-1-infected patients alone and in combination with
lamivudine and zidovudine. HIV Clin Trials. Jul-Aug 2001;2(4):307-316.
► Masuhr A, Mueller M, Simon V, Zwingers T, Kurowski M, Jessen H, Lauenroth-Mai E, Moll A,
Schranz D, Moecklinghoff C, Arasteh K. Predictors of treatment failure during highly active
antiretroviral therapy (racing trial). Eur J Med Res. Aug 30 2002;7(8):341-346.
► Arasteh K, Muller M. [Improving resistance profile, simplifying administration mode. New
antiretroviral drugs]. MMW Fortschr Med. Apr 9 2002;144 Suppl 1:66-70.
► Arasteh K. Denying history. Am Psychol. Apr 2004;59(3):182.
► Herzmann C, Duesberg U, Arasteh K. [New therapeutic strategies in HIV infection-immune
reconstitution and virus suppression]. Med Klin (Munich). Jun 15 2004;99(6):323-325.
► Arasteh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peeters M, Rinehart A,
Lefebvre E. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral
regimen: a 14-day proof-of-principle trial. AIDS. Jun 10 2005;19(9):943-947.
► Arasteh K, Muller M. [New drugs--hope for salvage patients?]. MMW Fortschr Med. Apr 25
2005;147 Spec No 1:38-41.
► Arasteh K, Stocker H. Tropism switch in patients infected with HIV-1 and its clinical implications for
the treatment with CCR5-receptor inhibitors. Eur J Med Res. Oct 15 2007;12(9):397-402.
► Traeder C, Kowoll S, Arasteh K. Candida infection in HIV positive patients 1985-2007. Mycoses.
Sep 2008;51 Suppl 2:58-61.
► Herzmann C, Arasteh K. Efavirenz-induced osteomalacia. AIDS. Jan 14 2009;23(2):274-275.
► Arasteh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Bethune MP, Peeters M,
Woodfall B. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who
have previously failed antiretroviral therapy. Antivir Ther. 2009;14(5):713-722.
► Arasteh K, Weitner L, Fenske S, Kuhlmann B, Freiwald M, Ebrahimi R, Gallo L, Ranneberg R,
Mertenskoetter T. Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of
emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT). Eur J Med Res.
May 14 2009;14(5):195-199.
► Arasteh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S,
Vangeneugden T, Tomaka F. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV
type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14(6):859-864.
► Hoffmann C, Schmid H, Muller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski
M, Horst HA, Reuter S, Vogel M, Jager H, Bogner J, Arasteh K. Improved outcome with rituximab in
patients with HIV-associated multicentric Castleman disease. Blood. Sep 29 2011;118(13):3499-3503.
19/1/15
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 2 / 7
Curriculum Vitae
Keikawus Arastéh
► Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E, Yong CL,
Robinson P, Quinson A. Twenty-four-week efficacy and safety of switching virologically suppressed
HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended
release 400 mg once daily (TRANxITION). HIV Med. Apr 2012;13(4):236-244.
Co-Author
► Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C,
Ait-Khaled M, Purdon S. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced
patients: results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS. May 5
2000;14(7):781-789.
► Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C,
Purdon S. Intensification of stable background therapy with abacavir in antiretroviral therapy
experienced patients: 48-week data from a randomized, double-blind trial. HIV Med. Jan
2001;2(1):27-34.
► Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters
M, Woodfall B, Stebbing J, vant' Klooster GA. An open-label assessment of TMC 125--a new, nextgeneration NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. Dec 5
2003;17(18):F49-54.
► Kreuter A, Reimann G, Esser S, Rasokat H, Hartmann M, Swoboda J, Conant MA, Tschachler E,
Arasteh K, Altmeyer P, Brockmeyer NH. [Screening and therapy of anal intraepithelial neoplasia (AIN)
and anal carcinoma in patients with HIV-infection]. Dtsch Med Wochenschr. Sep 19
2003;128(38):1957-1962.
► Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ,
Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M. Efficacy of
enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. May
29 2003;348(22):2186-2195.
► Dunay IR, Heimesaat MM, Bushrab FN, Muller RH, Stocker H, Arasteh K, Kurowski M, Fitzner R,
Borner K, Liesenfeld O. Atovaquone maintenance therapy prevents reactivation of toxoplasmic
encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother. Dec
2004;48(12):4848-4854.
► Salzberger B, Marcus U, Vielhaber B, Arasteh K, Golz J, Brockmeyer NH, Rockstroh J. GermanAustrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med
Res. Nov 29 2004;9(11):491-504.
► Scheller C, Ullrich A, McPherson K, Hefele B, Knoferle J, Lamla S, Olbrich AR, Stocker H, Arasteh
K, ter Meulen V, Rethwilm A, Koutsilieri E, Dittmer U. CpG oligodeoxynucleotides activate HIV
replication in latently infected human T cells. J Biol Chem. May 21 2004;279(21):21897-21902.
► Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Claus J, Jessen H, Cordes C, Hintsche B,
Schlote F, Schneider L, Kurowski M. Nevirapine significantly reduces the levels of racemic methadone
and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents
Chemother. Nov 2004;48(11):4148-4153.
► Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB,
Naderer OJ. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and
antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected
patients. Antimicrob Agents Chemother. Jan 2004;48(1):116-123.
► Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ.
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of
amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of
HIV-infected patients. Clin Infect Dis. Aug 15 2004;39(4):591-594.
► Herzmann C, Arasteh K, Murphy RL, Schulbin H, Kreckel P, Drauz D, Schinazi RF, Beard A,
Cartee L, Otto MJ. Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'thiacytidine with efavirenz and stavudine in antiretroviral-naive human immunodeficiency virusinfected patients. Antimicrob Agents Chemother. Jul 2005;49(7):2828-2833.
► Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas JG, Clotet B,
Danise A, Landman R, Proll S, Snowden W, Foreman R, Smith P. Comparison of gastrointestinal
tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet
formulations. HIV Med. Mar 2005;6(2):107-113.
► Lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K, Mauss S,
Rockstroh JK. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin
and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection.
Jun 2005;33(3):140-147.
19/1/15
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 3 / 7
Curriculum Vitae
Keikawus Arastéh
► Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner
JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Jr., Kuritzkes DR,
Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine
A, Guimaraes D, Demasi R, Chung J, Salgo MP. Durable efficacy of enfuvirtide over 48 weeks in
heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background
regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. Dec 1 2005;40(4):404-412.
► Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari
J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes
D, Eron JJ, Jr., Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B,
Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R,
Smiley L, Salgo MP. Safety of enfuvirtide in combination with an optimized background of
antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic
Syndr. Dec 1 2005;40(4):413-421.
► Weitzel T, Muhlberger N, Jelinek T, Schunk M, Ehrhardt S, Bogdan C, Arasteh K, Schneider T, Kern
WV, Fatkenheuer G, Boecken G, Zoller T, Probst M, Peters M, Weinke T, Gfrorer S, Klinker H,
Holthoff-Stich ML. Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance
network. Eur J Clin Microbiol Infect Dis. Jul 2005;24(7):471-476.
► Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, Lopez P, Clumeck N, Gerstoft
J, Stavrianeas N, Moreno S, Antunes F, Neubacher D, Mayers D. Ritonavir-boosted tipranavir
demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIVinfected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis. Nov 15 2006;43(10):13471356.
► Hentrich M, Maretta L, Chow KU, Bogner JR, Schurmann D, Neuhoff P, Jager H, Reichelt D, Vogel
M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P. Highly active antiretroviral therapy
(HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann
Oncol. Jun 2006;17(6):914-919.
► Stocker H, Kloft C, Plock N, Breske A, Kruse G, Herzmann C, Schulbin H, Kreckel P, Weber C,
Goebel F, Roeling J, Staszewski S, Plettenberg A, Moecklinghoff C, Arasteh K, Kurowski M.
Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents
Chemother. Feb 2006;50(2):667-673.
► Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, Sudeck H, Schmidt-Wolf
IG, Anagnostopoulos I, Huhn D. Acquired immunodeficiency syndrome-related lymphoma:
simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone
chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the
German Multicenter Trial. Cancer. Apr 1 2006;106(7):1560-1568.
► Gathe JC, Jr., Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG, Cooper D, Lazzarin A,
Kohlbrenner VM, Dohnanyi C, Sabo J, Mayers D. Efficacy and safety of three doses of tipranavir
boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum
Retroviruses. Feb 2007;23(2):216-223.
► Reynes J, Arasteh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C,
Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, M OH, Stellbrink HJ, Trottier
B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A,
Wilkinson M, Salgo MP. TORO: ninety-six-week virologic and immunologic response and safety
evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS.
Aug 2007;21(8):533-543.
► Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet.
2007;46(9):739-756.
► Stocker H, Herzmann C, Breske A, Kruse G, Berger M, Schulbin H, Hill A, Steinmuller J, Becker M,
Arasteh K, Kurowski M. Saquinavir, nelfinavir and M8 pharmacokinetics following combined
saquinavir, ritonavir and nelfinavir administration. J Antimicrob Chemother. Mar 2007;59(3):560-564.
► van Lunzen J, Liess H, Arasteh K, Walli R, Daut B, Schurmann D. Concomitant use of gastric acidreducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly
active antiretroviral therapy. HIV Med. May 2007;8(4):220-225.
► Kakuda TN, Scholler-Gyure M, Workman C, Arasteh K, Pozniak AL, De Smedt G, Beets G,
Peeters M, Vandermeulen K, Woodfall BJ, Hoetelmans RM. Single- and multiple-dose
pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Antivir Ther. 2008;13(5):655-661.
► Schulbin H, Bode H, Stocker H, Schmidt W, Zippel T, Loddenkemper C, Engelmann E, Epple HJ,
Arasteh K, Zeitz M, Ullrich R. Cytokine expression in the colonic mucosa of human immunodeficiency
virus-infected individuals before and during 9 months of antiretroviral therapy. Antimicrob Agents
19/1/15
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 4 / 7
Curriculum Vitae
Keikawus Arastéh
Chemother. Sep 2008;52(9):3377-3384.
► Battegay M, Arasteh K, Plettenberg A, Bogner JR, Livrozet JM, Witt MD, Mossdorf E, Yong CL,
Zhang W, Macha S, Berger F, Stern J, Robinson P, Quinson AM. Bioavailability of extended-release
nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Clin Ther. Sep 2011;33(9):13081320.
► Cooper DA, Cordery DV, Reiss P, Henry K, Nelson M, O'Hearn M, Reynes J, Arasteh K, Chung J,
Rowell L, Guimaraes D, Bertasso A. The effects of enfuvirtide therapy on body composition and
metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med. Jan
2011;12(1):31-39.
► Marretta L, Stocker H, Drauz D, Mueller M, Masuhr A, Dieckmann S, Wong V, Koch A, Grueneisen
A, Arasteh K, Weiss R. Treatment of HIV-related primary central nervous system lymphoma with AZT
high dose, HAART, interleukin-2 and foscarnet in three patients. Eur J Med Res. May 12
2011;16(5):197-205.
► Soriano V, Arasteh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G,
Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L. Nevirapine versus
atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviralnaive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16(3):339-348.
► von Kleist M, Menz S, Stocker H, Arasteh K, Schutte C, Huisinga W. HIV quasispecies dynamics
during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in
latent reservoirs. PLoS One. 2011;6(3):e18204.
► Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse
A, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Kukolj G, Nehmiz G,
Haefner C, Boecher WO. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127,
and ribavirin in patients with chronic HCV infection. Gastroenterology. Dec 2011;141(6):2047-2055;
quiz e2014.
► Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme
R, Arasteh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO,
Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Bocher W, Steffgen J. Rapid
and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in
combination with peginterferon alfa 2a and ribavirin. J Hepatol. Jul 2012;57(1):39-46.
► Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, Fatkenheuer G, Seidel E,
Nickelsen M, Wolf T, Rieke A, Schurmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A,
Arasteh K, Hoffmann C. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a
prospective multicenter study. J Clin Oncol. Nov 20 2012;30(33):4117-4123.
► Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, Mohapi L, Short W, Crauwels H,
Vanveggel S, Boven K. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. Aug
2012;13(7):406-415.
► Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, Dejesus E, Antunes F, Arasteh K,
Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK.
Cobicistat versus ritonavir as a pharmacoenhancer for atazanavir plus emtricitabine/tenofovir DF in
treatment-naive HIV-1-infected patients: Week 48 results. J Infect Dis. Mar 26 2013.
► Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse
AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G,
Bocher WO, Mensa FJ. Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatmentnaive HCV genotype 1: SOUND-C1 final results. Antivir Ther. Apr 4 2013.
► Jacobson, Asselah, Ferenci, Foster, Jensen, Negro, Mantry, Wright, Forns, Garcia-Samaniego,
Oliveira, Carvalho, Forton, Arastéh, Cooper, Ghesquiere, Dufour, Sakai, Tanaka, Stern, Sha, Boecher,
Steinmann, Quinson, on behalf of the STARTVerso3 Study Group. STARTVerso 3: A randomized,
double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon
alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection ,
American Association for the Study of the Liver: The Liver Meeting 2013. Poster Number 1100
► Jürgen Kurt Rockstroh, Mark Nelson, Vicente Soriano, Keikawus Arastéh, Josep Guardiola, Sanjay
Bhagani, Josep Mallolas, Cristina Tural, Massimo Puoti, Patrick Ingiliz, Manuel Battega, Mamta K.
Jain, Marina Nunez, Kristen Marks, Jens Kort, Jerry Stern, Richard Vinisko, Montserrat Manero,
Douglas Dieterich. STARTVerso 4 Phase III Trial of Faldaprevir Once-daily Plus Peg Interferon Alfa-2a
and Ribavirin (PR) in Patients with HIV and HCV Genotype 1 Coinfection: End of Treatment
Response (ETR) 14th European AIDS Conference (EACS), 16.-19. October 2013
► Stellbrink, Hans-Jürgen; Arastéh, Keikawus; Schürmann, Dirk; Stephan, Christoph; Dierynck, Inge;
Smyej, Ilham; Hoetelmans, Richard M. W.; Truyers, Carla; Meyvisch, Paul ; Jacquemyn, Bert; Mariën,
19/1/15
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 5 / 7
Curriculum Vitae
Keikawus Arastéh
Kris; Simmen, Kenneth; Verloes, René. Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1
Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naive HIV-1–Infected
Patients JAIDS Journal of Acquired Immune Deficiency Syndromes:1 March 2014 - Volume 65 Issue 3 - p 283–289
► Douglas Dieterich, Cristina Tural, Mark Nelson, Keikawus Arastéh, Vicente Soriano, Josep
Guardiola, Sanjay Bhagani, Jürgen K Rockstroh, Jerry O Stern, Anne-Marie Quinson. Faldaprevir
Plus Pegylated Interferon α-2a/Ribavirin in HIV/HCV Co-infection: STARTVerso4 The 2014
Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2014
► Mark Nelson, Keikawus Arastéh, Mamta K Jain, Vicente Soriano, José Valdez Madruga, Juvencio
Furtado, Manuel Battegay, Fenglei Huang, Montserrat Manero, Douglas Dieterich. Effect of
Faldaprevir on Atazanavir Pharmacokinetics in Patients with HIV/HCV Co-Infection The 2014
Conference on Retroviruses and Opportunistic Infections (CROI), March 3–6, 2014
► J. O. Morales-Ramirez, J. M. Gatell, D. P. Hagins, M. Thompson, K. Arasteh, C. Hoffmann, C.
Harvey, X. Xu, H. Teppler . Safety and Antiviral Effect of MK-1439, a Novel NNRTI, (+Truvada®) in
ART-Naive HIV Infected Patients The 2014 Conference on Retroviruses and Opportunistic Infections
(CROI), March 3–6, 2014
► Douglas Dieterich, Peter Ferenci, Ira M Jacobson, Francesco Negro, Massimo Puoti5, Jürgen K
Rockstroh, Michael P Manns, Keikawus Arastéh, Célia Oliveira, Jean-François Dufour, Elmar Zehnter,
Clifford Leen, Sanjay Bhagani, Jerry O Stern, Anne-Marie Quinson, Joseph Scherer, Montserrat
Manero, Donald M Jensen. SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND
HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENTNAÏVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS 49th
Annual Meeting of the European Association for the Study of the Liver (EASL), April 9–13, 2014
Guidelines
► Arasteh K, Bader A, Berg T, Blauhut B, Bogner J, Brockhaus W, Brockmeyer N, Brodt H, Dalhoff K,
Doerr H, Dupke S, Esser S, Fleckenstein B, Goebel F, Gölz J, Grosch-Wörner I, Gross G, Gürtler L,
Hartmann H, Helm E, Hoffmann C, Jäger H, Jarke J, Jablonowski H, Junginger T, Kern P, Knechten
H, Körner T, Korn K, Kramer A, Kräuslich H, Kurowski M, Lechl P, Lessy D, Marcus U, Mauss S, Moll
A, Müller W, Pfeil B, Pistner H, Plettenberg A, Rasokat H, Reimann G, Remé T, Rieger A, Röcken M,
Rockstroh J, Ruf B, Rump J, Salzberger B, Schafberger B, Schedel I, Schmied B, Schmidt R,
Schramm W, Schrappe M, Shah P, Staszewski S, Stellbrink H, Stoehr A, Stoll M, Thoma-Greber E,
Tschachler E, Überla K, Vetter N, Zangerle R.
Deutsch-Österreichische Leitlinien zur postexpositionellen Prophylaxe der HIV-Infektion. Dtsch Med
Wochenschr 2003,128:36-50.
► Arasteh K, Bader A, Berg T, Blauhut B, Bogner J, Brockhaus W, Brockmeyer N, Brodt H, Doerr H,
Dupke S, Esser S, Fleckenstein B, Goebel F, Gölz J, Grosch-Wörner I, Gross G, Gürtler L, Hartmann
H, Helm E, Hoffmann C, Jäger H, Jablonowski H, Kern P, Knechten H, Körner T, Korn K, Kramer A,
Kräuslich H, Kurowski M, Marcus U, Moll A, Pfeil B, Plettenberg A, Rasokat H, Reimann G, Rieger A,
Rockstroh J, Ruf B, Rump J, Salzberger B, Schafberger B, Schedel I, Schmied B, Schmidt B, Schmidt
R, Shah P, Schöfer H, Schrappe M, Staszewski S, Stellbrink H, Stoehr A, Stocker H, Stoll M,
Tschachler E, Überla K, Vetter N, Zangerle R.
Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV Infektion. Dtsch Med
Wochenschr 2003,128:7-18.
► Salzberger B, Marcus U, Vielhaber B, Arasteh K, Golz J, Brockmeyer NH, Rockstroh J.
German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004).
Eur J Med Res 2004,9:491-504.
Books / Book Chapters
► Buchveröffentlichung als Autor (Rudolf Weiß und Keikawus Arastéh): „Buch gegen die Panik –
Leben mit der HIV-Infektion“, 9 Auflagen, Erstausgabe 1994, 9. Auflage 2007
► Mitautor Buchkapitel „HIV-Infektion und AIDS“ im Buch „Duale Reihe - Innere Medizin“ Thieme
Verlag, 2. Auflage, 2009
Projects
Memberships
► Active Member Expertenpanel „RADATA“ des Instituts für Interdisziplinäre Medizin
(Expertenratsystem zur Optimierung antiretroviraler Therapieentscheidungen)
► Active Member Editorial Boards des Journals „BioMed Research Internaional”, Hindawi Publishing
19/1/15
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 6 / 7
Curriculum Vitae
Keikawus Arastéh
Corporation
► Active Member Editorial Boards des Journals „ISRN AIDS”, Hindawi Publishing Corporation
► Active Member Editorial Boards des Journals „Infection”, Springer Journals
► Active Member Editorial Boards des Journals „Journal of AIDS & Clinical Research”, Journal of
AIDS & Clinical Research
► Active Member Editorial Boards des Journals „JOURNAL OF AIDS & ITS RESEARCH (IJAR)”,
Nuclei Online publishing group
► Active Member Editorial Boards des Journals „BioMed Research Internaional”, Hindawi Publishing
Corporation
► Active Member Editorial Boards des Journals „ISRN AIDS”, Hindawi Publishing Corporation
► Active Member Editorial Boards des Journals „Infection”, Springer Journals
► Active Member Editorial Boards des Journals „Journal of AIDS & Clinical Research”, Journal of
AIDS & Clinical Research
► Active Member Editorial Boards des Journals „JOURNAL OF AIDS & ITS RESEARCH (IJAR)”,
Nuclei Online publishing group
Other Relevant Information
19/1/15
Gilead HIV Clinical Cooparation Grant for the project Clinical Research and Education with Donetsk
Regional Center of AIDS Prevention and Control, UA, Juni 2007
© European Union, 2002-2014 | http://europass.cedefop.europa.eu
Page 7 / 7